ArticleBMC chemistry2026
Novel indole-based scaffolds: Design, synthesis, molecular modeling, and anti-proliferative evaluation.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis and crystal structure of 4,6-di-amino-3-(prop-2-en-1-yl)-2-sulfanyl-idene-2,3-di-hydro-1,3,5-triazin-1-ium chloride.Acta crystallographica. Section E, Crystallographic communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two novel series of indole-based scaffolds have been designed, synthesized, and screened for their anti-proliferative activities on the NCI-60 cell line panel. The novel structures of the indole-sulfonate and indole-aspirin mimic conjugates were designed as cyclin-dependent kinase 2 (CDK-2) inhibitors. The design approach depends on molecular hybridization between the indole scaffold and alkanesulfonates or with aspirin mimic analogs. The synthesized compounds were screened for their cytotoxic activity at a concentration of 10 µM. Compound 8a exhibited the most potent anticancer activity among the tested series and was further selected for the five-dose stage. At sub-micromolar doses, compound 8a showed anti-cancer potency against a panel of 60 tumor cell lines, with log GI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.